Fundz Deep Dive
Everything you need to win BioNTech — in one platform.
Who to reach, what to say, and why now on BioNTech — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on BioNTech — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
BioNTech Acquires Biotheus, Gains Control of Investigational Bispecific Antibody
Nov 13, 2024•over 1 year ago
Contract Type
partnership
MainzBiotechnologyHealth CareTherapeuticsBiopharmaDescription
BioNTech has announced the acquisition of development partner Biotheus, which includes gaining full control of an investigational bispecific antibody aimed at dethroning checkpoint inhibitors as the standard treatment for solid tumors. The agreement involves an $800 million upfront payment, along with the promise of up to $150 million in certain milestones.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months